Sales/Profit and loss

Overview of financial results for FY2023

The Group is actively engaged in the healthcare business and the school DX business, both of which are expected to expand in the future, in order to enhance its corporate value over the medium to long term.
During the current fiscal year under review, consolidated net sales stood at ¥26,798 million (up 1.2% year on year) and gross profit at ¥18,373 million (down 1.7 % year on year), attributable to an increase in cost of sales.
Operating income stood at ¥298 million (down 65.7 % year on year)) due to an increase in selling, general and administrative expenses due chiefly to a rise in advertising expenses.
Ordinary income stood at ¥458 million (down 5.7% year on year) chiefly due to a share of profit of entities accounted for using equity method of ¥102 million (compared to a share of loss of entities accounted for using equity method of ¥457 million in the previous year).
Profit attributable to owners of parent amounted to ¥753 million (a loss of ¥930 million in the previous fiscal year) as a result of a significant increase in extraordinary income due to consumption taxes refund and gain on change in equity and a substantial decrease in extraordinary losses compared from the previous fiscal year.

Consolidated statements of income

(Millions of yen)

              
  2019/9 2020/9 2021/9 2022/9 2023/9
Net sales27,112 26,082 25,743 26,479 26,798
Operating income 2,959 2,507 1,929 870 298
Operating income ratio(%) 10.9 9.6 7.5 3.3 1.1
Ordinary income 3,134 2,082 1,370 485 458
Ordinary income ratio(%) 11.6 8.0 5.3 1.8 1.7
Profit attributable to owners of parent 1,508 506 (1,164) (930) 753
Profit attributable to owners of parent ratio(%) 5.6 1.9 (4.5) (3.5) (2.8)